Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George O'Neil

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Environmental Health Perspectives|July 20, 2007
Superfund: evaluating the impact of executive order 12898Sandra George O'Neil
Journal of Psychopharmacology (Oxford, England)|February 21, 2014
Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case reportErin Kelty, Vlad Martyn, George O'Neil, et al.
Drug Development and Industrial Pharmacy|February 4, 2006
In vitro and in vivo release of naltrexone from biodegradable depot systemsYandi Liu, V Bruce Sunderland, A George O'Neil
Journal of Psychopharmacology (Oxford, England)|May 19, 2012
Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case seriesGary Hulse, George O'Neil, Noella Morris, et al.
Journal of Human Lactation : Official Journal of International Lactation Consultant Association|August 7, 2004
Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milkCarol F Chan, Madhu Page-Sharp, Judith H Kristensen, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implantsGary P Jeffrey, Gerry MacQuillan, Fern Chua, et al.
Journal of Psychopharmacology (Oxford, England)|June 7, 2014
Changes in hospital and out-patient events and costs following implant naltrexone treatment for problematic alcohol useErin Kelty, Lesleigh Hayes, Graeme O'Neil, et al.
Addiction Biology|September 18, 2003
Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdosesDiane E Arnold-Reed, Gary K Hulse, Robert C Hansson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Environmental Health Perspectives|July 20, 2007
Superfund: evaluating the impact of executive order 12898Sandra George O'Neil
Journal of Psychopharmacology (Oxford, England)|February 21, 2014
Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case reportErin Kelty, Vlad Martyn, George O'Neil, et al.
Drug Development and Industrial Pharmacy|February 4, 2006
In vitro and in vivo release of naltrexone from biodegradable depot systemsYandi Liu, V Bruce Sunderland, A George O'Neil
Journal of Psychopharmacology (Oxford, England)|May 19, 2012
Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case seriesGary Hulse, George O'Neil, Noella Morris, et al.
Journal of Human Lactation : Official Journal of International Lactation Consultant Association|August 7, 2004
Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milkCarol F Chan, Madhu Page-Sharp, Judith H Kristensen, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implantsGary P Jeffrey, Gerry MacQuillan, Fern Chua, et al.
Journal of Psychopharmacology (Oxford, England)|June 7, 2014
Changes in hospital and out-patient events and costs following implant naltrexone treatment for problematic alcohol useErin Kelty, Lesleigh Hayes, Graeme O'Neil, et al.
Addiction Biology|September 18, 2003
Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdosesDiane E Arnold-Reed, Gary K Hulse, Robert C Hansson, et al.
Pageof 1